Muramyl Dipeptide Modulation of TLR Pathways for Inflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies fail to effectively modulate Toll-like receptors (TLR) to reduce inflammation across multiple pathways, which is necessary for treating various inflammatory conditions such as autoimmune disorders, infections, and inflammatory bowel disease.

Innovation Solution

Administration of a muramyl dipeptide (MDP) composition that modulates IRF4 levels and activity, thereby inhibiting multiple TLR pathways and reducing cytokine responses to TLR ligands, thereby addressing excessive inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional therapies are used to treat inflammation, then treatment is provided for specific inflammatory conditions, but they fail to effectively modulate multiple TLR pathways simultaneously

Engineering Contradiction:

Improveability to modulate multiple TLR pathwaysVSAvoideffectiveness in reducing inflammation

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies universality by using a single compound (muramyl dipeptide or MDP) to perform multiple functions across different TLR pathways. MDP simultaneously modulates TLR2, TLR4, and other Toll-like receptor pathways, making one therapeutic agent capable of addressing multiple inflammatory mechanisms that conventional single-pathway therapies cannot target effectively

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent employs MDP as an intermediary substance that mediates the modulation of multiple TLR pathways. MDP acts as a bridging molecule that interacts with various TLR receptors and downstream signaling components (such as MyD88, TRIF, and IRAK kinases), thereby coordinating the immune response across multiple pathways in a controlled manner

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If TLR signaling is activated to provide immune defense, then pathogen detection and response are enhanced, but excessive signaling leads to inflammation and tissue damage

Engineering Contradiction:

Improveimmune defense capabilityVSAvoidinflammation and tissue damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by using MDP to pre-modulate TLR pathways before excessive inflammatory signaling occurs. MDP administration in advance or during early stages of inflammation prevents the runaway activation of TLR signaling, thereby blocking the progression to severe inflammation and tissue damage while maintaining necessary immune defense

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The patent converts the harmful effect of excessive TLR signaling into a beneficial outcome by using MDP to harness the same TLR pathways for protective immunity. MDP stimulates controlled TLR activation that enhances pathogen detection and immune response while simultaneously preventing the harmful inflammation through balanced modulation of downstream signaling

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS8603978B2Use of muramyl dipeptide (MDP) for treating inflammation

Publication Date: 2013.12.10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

AI summary

The present invention provides a method of treating or preventing inflammation in a subject comprising administering to the subject an effective amount of a muramyl dipeptide (MDP).